Ketodarolutamide

Ketodarolutamide is a nonsteroidal antiandrogen (NSAA) that is under investigation for the treatment of prostate cancer. It is a derivative of darolutamide, a drug that is already approved for the treatment of non-metastatic castration-resistant prostate cancer.

Mechanism of Action[edit | edit source]

Ketodarolutamide, like other NSAAs, works by binding to the androgen receptor and preventing it from activating. This inhibits the growth of prostate cancer cells, which rely on androgens for growth and survival. The "keto" in its name refers to a ketone group that has been added to the darolutamide molecule, which may enhance its antiandrogen activity.

Clinical Trials[edit | edit source]

As of 2021, ketodarolutamide is in Phase I clinical trials for the treatment of prostate cancer. These trials are designed to assess the safety, tolerability, and pharmacokinetics of the drug in humans. If successful, the drug will proceed to Phase II clinical trials, which will evaluate its efficacy in a larger group of patients.

Potential Advantages[edit | edit source]

Ketodarolutamide may offer several advantages over existing NSAAs. First, it may have greater antiandrogen activity due to the addition of the ketone group. Second, it may have a better safety profile, as it is nonsteroidal and therefore less likely to cause side effects associated with steroid use. Finally, it may be effective in patients who have become resistant to other NSAAs, offering a new treatment option for this difficult-to-treat population.